Through the April 2025 OPPS quarterly update CR (Transmittal 13135, Change Request 13993, dated March 20, 2025), we recognized several new HCPCS codes for payment under the OPPS
An important limitation of the available RCTs is the lack of standardization in supplement dosing and the variable bioavailability of these compounds, which May contribute to the heterogeneity of clinical outcomes
However, the regression of benefits upon stopping treatment highlights the need for sustained administration to prolong its positive effects
Patients may experience diarrhea, bloating, weight loss, and micronutrient deficiency, with downstream impacts on function, quality of life, and survival [3,6]
In type 2 diabetes, numerous clinical trials have shown that Semaglutide significantly reduces HbA1c levels, a measure of long-term blood sugar control, when compared to placebo or other antidiabetic medications
The rates of cardiovascular death, and death from any cause, were lower in the liraglutide group than in the placebo group (4.7% vs
